Related Experiment Video
Updated: Feb 7, 2026
Screening Foodstuffs for Class 1 Integrons and Gene Cassettes
Published on: June 19, 2015
Real-world occurrence, therapy, and outcome of patients with class 2 or 3 BRAF compared with class 1 BRAF-mutated
S Pradervand1, N Freundler1, B Gosztonyi2
1Centre Hospitalier Universitaire Vaudois - CHUV, Department of Oncology, Lausanne.
Background:
BRAF V600 mutations are the epitome of targeted therapy. However, not much is known about non-V600 mutations. Using the new data infrastructure of the Swiss Personalized Oncology project of the Swiss Personalized Health Network (SPHN), we evaluated the fate of patients with cancer with non-V600 BRAF mutations in comparison to patients with class 1 mutations.
Patients And Methods:
In this retrospective observational multicenter study, we have assembled a cohort of 392 patients with class 1 and 154 patients with nonclass 1 BRAF mutations (76 colorectal cancers, 96 lung cancers, 297 melanomas, and 77 other cancers). We carried out outcome analyses between mutational classes and therapeutic subgroups.
Results:
Overall survival (OS) did not differ significantly between patients with class 1 and nonclass 1 mutations. Upon treatment with BRAF/MEK inhibitors, patients with class 1 mutant melanoma showed numerically longer progression-free survival (PFS; 217 days) than patients with nonclass 1 mutant disease (73 days). Overall, in patients with class 2 or 3 mutations, BRAF and MEK inhibitors showed no benefit over other systemic therapies. However, specific class 2 mutations such as K601E may confer sensitivity to BRAF/MEK inhibitors, with two out of five patients achieving a PFS >400 days.
Conclusions:
The diversity of BRAF mutations presents significant treatment challenges. Despite similar OS, nonclass 1 mutant tumors showed a trend toward lower PFS with BRAF/MEK blockade. Selected class 2 mutations may confer sensitivity to BRAF/MEK inhibitors. This highlights the rationale for a mutation, rather than class-specific, clinical approach against nonclass 1 BRAF-mutant tumors.
Insights
Non-V600 BRAF mutations present treatment challenges. While overall survival is similar, non-V600 BRAF-mutant cancers show lower progression-free survival with BRAF/MEK inhibitors, though some mutations may respond.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- BRAF V600 mutations are established targets for cancer therapy.
- Limited understanding exists regarding the clinical implications of non-V600 BRAF mutations.
- Utilizing the Swiss Personalized Oncology data infrastructure, this study compares outcomes for patients with non-V600 BRAF mutations versus class 1 mutations.
Purpose of the Study:
- To evaluate the clinical outcomes of patients with non-V600 BRAF mutations.
- To compare the efficacy of BRAF/MEK inhibitors in patients with different BRAF mutation classes.
- To identify potential therapeutic strategies for non-V600 BRAF-mutant cancers.
Main Methods:
- Retrospective observational multicenter study.
- Cohort of 392 patients with class 1 BRAF mutations and 154 with nonclass 1 BRAF mutations.
- Analysis of overall survival (OS) and progression-free survival (PFS) based on mutation class and treatment subgroups.
Main Results:
- No significant difference in OS between class 1 and nonclass 1 BRAF mutation groups.
- BRAF/MEK inhibitors showed numerically longer PFS in class 1 mutant melanoma (217 days) vs. nonclass 1 (73 days).
- BRAF/MEK inhibitors offered no significant benefit over other therapies for class 2 or 3 mutations, except for specific mutations like K601E.
Conclusions:
- Nonclass 1 BRAF mutations pose therapeutic challenges, with a trend towards lower PFS under BRAF/MEK blockade despite similar OS.
- Specific nonclass 1 mutations, such as class 2 K601E, may indicate sensitivity to BRAF/MEK inhibitors.
- A mutation-specific, rather than class-specific, approach is warranted for treating nonclass 1 BRAF-mutant tumors.
More Related Videos
Related Concept Videos
01:25Drug Classes and Categories
01:25Antibody Structure and Classes
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers